Immunobiology of pleural inflammation: Potential implications for pathogenesis, diagnosis and therapy

European Respiratory Journal

Volumn 10, Issue 10, 1997, Pages 2411-2418

  Kroegel, C ^a   Antony, V B ^b  

^a FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^b INDIANA UNIVERSITY   (United States)

Author keywords

Mechanism of pleurodesis; Pathogenesis; Pleural cell infiltration; Pleural disease; Pleural fluid cytokines; Pleural immune response

Indexed keywords

ADENOSINE DEAMINASE; ANTIOXIDANT; COLLAGEN; CYTOKINE; INTERLEUKIN 8; LYSOZYME; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR;

CELL INFILTRATION; HUMAN; IMMUNE RESPONSE; IMMUNOBIOLOGY; MEDIATOR RELEASE; NONHUMAN; PLEURISY; PLEURODESIS; PRIORITY JOURNAL; REVIEW;

CELLS, CULTURED; HUMANS; PLEURA; PLEURAL NEOPLASMS; PLEURISY; PLEURODESIS; TUBERCULOSIS, PLEURAL;

EID: 0030663232     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.97.10102411     Document Type: Review

References (78)

1. Light RW. In: Pleural diseases. Lea & Febiger, Philadelphia, 1990.
2. Antony VB, Rothfuss KJ, Godbey SW, Sparks JA, Hott JW. Mechanism of tertacycline-hydrochloride-induced pleurodesis. Tertacycline-hydrochloride-stimulated mesothelial cells produce a growth-factor like activity for fibroblasts. Am Rev Respir Dis 1992; 146: 1009-1013.
3. Schmitter D, Lauber B, Fagg B, Stahel RA. Haemopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int J Cancer 1992; 51: 296-301.
4. Antony VB, Godbey SW, Kunkel SL, et al. Recruitment of inflammatory cells to the pleura space: Chemotactic cytokines IL-8, and monocyte chemotactic peptide-1 in human pleural fluids. J Immunol 1993; 151: 7216-7223.
5. Boylan AM, Ruegg C, Kim KJ, et al. Evidence of a role for mesothelial cell-derived interleukin-8 in the pathogenesis of asbestos-induced pleurisy in rabbits. J Clin Invest 1992; 89: 1257-1267.
6. Antony VB, Godbey SW, Kunkel SL, et al. Pleural mesothelial cell expression of C-C (monocyte chemotactic peptide [MCP-1]) and C-X-C (Interleukin-8 [IL-8]) chemokine. Am J Respir Cell Mol Biol 1995; 12: 581-588.
7. Padock FK. The diagnostic significance of serous fluids in disease. N Engl J Med 1940; 223: 1010-1014.
8. Hofstetter M, Luttmann W, Kortsik C, Virchow JC jr, Matthys H, Kroegel C. Discrepancy between eosinophil counts and eosinophil cationic protein (ECP) in malignant pleural effusion. Eur Respir J 1995; 8: 205s.
9. Spriggs AI. Pleural eosinophilia due to pneumothorax. Acta Cytol (Baltimore) 1979; 23: 425.
10. Johnson RJ, Johnson JR. Paragonimiasis in Indochinese refugees: roentgenographic findings with clinical correlations. Am Rev Respir Dis 1983; 128: 534-538.
11. Kroegel C, Warner JA, Matthys H, Virchow JC Jr. Pulmonary immune cells in health and disease. The eosinophil leukocyte. Part II. Eur Respir J 1994; 7: 743-760.
12. Oda M, Satouchi K, Ikeda I, Sakakura M, Yasunga K, Saito K. The presence of platelet-activating factor associated with eosinophil and/or neutrophil accumulation in the pleural fluids. Am Rev Respir Dis 1990; 141: 1469-1473.
13. Yam LT. Diagnostic significance of lymphocytes in pleural effusions. Ann Intern Med 1967; 66: 972-982.
14. Domagala W, Emeson EE, Koss LG. T and B lymphocyte enumeration in the diagnosis of lymphoyte-rich pleural fluids. Acta Cytol 1981; 25: 108-110.
15. Bergroth V, Konttinen YT, Nordstrom D, Petterson T, Tolvanen E. Lymphocyte subpopulations, activation phenotypes, and spontaneous proliferation in tuberculous pleural effusions. Chest 1987; 91: 338-341.
16. Baganha MF, Pego A, Lima MA, Gaspar EV, Pharm B, Cordeiro AR. Serum and pleural adenosine deaminase: correlation with lymphocytic populations. Chest 1990; 97: 605-610.
17. Takahashi K, Sone S, Kimura S, Ogura T, Monden Y. Phenotypes and lymphokine-activated killer activity of pleural cavity lymphocytes of lung cancer patients without malignant effusion. Chest 1993; 103: 1732-1738.
18. Lucivero G, Pierucci G, Bonomo L. Lymphocyte subsets in peripheral blood and pleural fluid. Eur Respir J 1988; 1: 337-340.
19. Hansen K, Mossman BT. Generation of superoxide from alveolar macrophages exposed to asbestiform fibers and nonfibrous particulates. Cancer Res 1987; 47: 1681-1686.
20. Donaldson K, Cullen RT. Chemiluminescence of asbestos-activated macrophages. Br J Exp Pathol 1984; 65: 81-90.
21. Baumann M, Heinrich K, Sahn SA, Strange C. Pleural macrophages differentially alter mesothelial cell growth and collagen production. Inflammation 1993; 17: 1-12.
22. Gjomarkaj M, Pace E, Melis M, Spatafora M, Toews GB. Mononuclear cells in exudative malignant pleural effusions. Characterization of pleural phagocytic cells. Chest 1994; 106: 1042-1049.
23. Christmas TI, Mutsaers SE, Manning LS, Davis MR, Robinson BWS. Platelet-growth factor as an autocrine factor in murine malignant mesothelioma. Eur Respir Rev 1993; 3: 192-194.
24. Fitzpatrick DR, Peroni DJ, Bielefeld-Ohmann H. The role of growth factors and cytokines in the tumorigenesis and immunobiology of malignant mesothelioma. Am J Respir Cell Biol 1995; 12: 455-460.
25. Jonjic N, Peri G, Bernasconi S, et al. Expression of adhesion molecules and chemotactic cytokines in cultured human mesothelial cells. J Exp Med 1992; 176: 1165-1174.
26. Antony VB, Hadley KJ, Sahn SA: Mechanism of pleural fibrosis in empyema: pleural macrophage mediated inhibition of fibroblast proliferation. Chest 1989; 95: S230-S231.
27. Tracey WR, Nakane M, Kuk J, et al. The nitric oxide synthetase inhibitor: L-NG-monomethylarginine, reduces carrageenan-induced pleurisy in the rat. J Pharmacol Exp Ther 1995; 273: 1295-1299.
28. Owens MW, Grisham MB. Nitric oxide synthesis by rat pleural mesothelial cells: induction by cytokines and lipopolysaccharide. Am J Physiol 1993; 265:L110-L116.
29. Janssen YMW, Marsh JP, Absher MP, et al. Oxidant stress response in human pleural mesothelial cells exposed to asbestos. Am J Respir Crit Care Med 1994; 149: 795-802.
30. Idell S, Zwieb C, Kumar A, Koenig KB, Johnson AR. Pathways of fibrin turnover of human pleural mesothelial cells in vitro. Am J Respir Cell Mol Biol 1992; 7: 414-426.
31. Philip-Joet F, Alessi MC, Philip-Joet C, et al. Fibrinolytic and inflammatory processes in pleural effusions. Eur Respir J 1995; 8: 1352-1356.
32. Spriggs AI, Boddington MM. The cytology of effusions. The Cytology of Effusions, 2nd Edition, Grune & Stratton, New York, 1968.
33. Tuomanen EI, Austrain R, Msure HR. Pathogenesis of pneumococcal infection. N Engl J Med 1995; 332: 1280-1284.
34. Heumann D, Barras C, Severin A, Glauser MP, Tomasz A. Gram-positive cell walls stimulate synthesis of tumor necrosis factor alpha and interleukin-6 by human monocytes. Infect Immun 1994; 62: 2715-2721.
35. Cabellos C, MacIntyre DE, Forrest M, Burroughs M, Prasad S, Tuomanen E. Differing roles for platelet activating factor during inflammation of the lung and subarachnoid space: the special case of Streptococcus pneumoniae. J Clin Invest 1992; 90: 612-618.
36. Geelen S, Bhattacharyya C, Tuomanen E. Induction of procoagulant activity on human endothelial cells by Streptococcus pneumoniae. Infect Immun 1992; 60: 4179-4183.
37. Seibert AF, Haynes J, Middleton R, Bass JB. Tuberculous pleural effusion: twenty-year experience. Chest 1991: 99: 883-886.
38. Metha JB, Dutt A, Harvill L, Mathews KM. Epidemiology of extrapulmonary tuberculosis. Chest 1991; 99: 1134-1138.
39. Stead WW, Eichenholz A, Strauss HK. Operative and pathologic findings in twenty-four patients with syndrome of idiopathic pleurisy with effusion, presumably tuberculous. Am Rev Respir Dis 1955; 71: 473-479.
40. Allen JC, Apicella MA. Experimental pleural effusions as a manifestation of delayed hypersensitivity to tuberculin PPD. J Immunol 1968; 101: 481-487.
41. Fujiwara H, Tsuyuguchi I. Frequency of tuberculin-reactive T-lymphocytes in pleural fluid and blood from patients with tuberculous pleurisy. Chest 1986; 89: 530-537.
42. Ribera E, Ocana I, Matinez-Vazquez JM, Rossell M, Espanol T, Ruibal A. High levels of interferon gamma in tuberculous pleural effusion. Chest 1988; 93: 308-311.
43. Ribera E, Esponol T, Matinez-Vazquez JM, Ocana I, Encabo G. Lymphocyte proliferation and gamma-interferon production after in vitro stimulation with PPD: differences between tuberculous and non-tuberculous pleurisy in patients with positive tuberculin skin test. Chest 1990; 97: 1381-1385.
44. Barnes PF, Grisso CL, Abrams JS, Band H, Rea TH, Modlin RL. Gamma delta T-lymphocytes in human tuberculosis. J Infect Dis 1992; 165: 506-512.
45. Valdes L, Jose ES, Alvarez D, et al. Diagnosis of tuberculous pleurisy using the biologic parameters adenosine deaminase, lysozyme, and interferon gamma. Chest 1993; 103: 458-465.
46. Villena V, Lopez-Encuentra A, Echave-Sustaeta J, et al. Interferon-γ in 388 immunocompromised and immunocompetent patients for diagnosing pleural tuberculosis. Eur Respir J 1996; 9: 2635-2639.
47. Söderblom T, Nyberg P, Teppo AM, Klockars M, Riska H, Pettersson T. Pleural fluid interferon-γ and tumor necrosis factor-α in tuberculous and rheumatoid pleurisy. Eur Respir J 1996; 9: 1652-1655.
48. Valdes L, San Jose E, Alvarez D, Valle JM. Adenosine deaminase (ADA) isoenzyme analysis in pleural effusions: diagnostic role, and relevance to the origin of increased ADA in tuberculous pleurisy. Eur Respir J 1996; 9: 747-751.
49. Gakis C. Adenosine deaminase (ADA) isoenzymes ADA1 and ADA2: diagnostic and biological role. Eur Respir J 1996; 9: 632-633.
50. Barnes PF, Fong SJ, Brennan PJ, Twonmey PE, Mazumder A, Modlin RL. Local production of tumor necrosis factor and IFN-gamma in tuberculous pleuritis. J Immunol 1985; 145: 149-154.
51. Maeda J, Ueki N, Ohkawa T, et al. Local production and localization of transforming growth factor-beta in tuberculous pleurisy. Clin Exp Immunol 1993; 92: 32-38.
52. Yanagawa H, Yano S, Haku T, Ohmoto Y, Sone S. Interleukin-1 receptor antagonist in pleural effusion due to inflammatory and malignant lung disease. Eur Respir J 1996; 9: 1211-1216.
53. Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in Brirain. Lancet 1995; 345: 535-539.
54. Heintz, NH, Janssen YMW, Mossman BT. Persistent induction of c-fos and c-jun expression by asbestos. Proc Natl Acad Sci 1993; 90: 3299-3303.
55. Marsh JP, Mossman BT. Role of asbestos and active oxygen species in activation and expression of ornithine decarboxylase in hamster tracheal epithelial cells. Cancer Res 1991; 51: 167-173.
56. Upham JW, Garlepp MJ, Musk AW, Robinson BWS. Malignant mesothelioma: new insights into tumour biology and immunology as a basis for new treatment approaches. Thorax 1995; 50: 887-893.
57. Lasky JA, Coin PG, Lindroos PM, Ostrowski LE, Brody AR, Bonner JC. Chrysotile asbestos stimulates platelet-derived growth factor-AA production by rat lung fibroblasts in vitro: evidence for an autocrine loop. Am J Respir Cell Mol Biol 1995; 12: 162-170.
58. Senior RM, Skodgen WF, Griffen GL, Wilner GD. Effects of fibrinogen derivatives upon the inflammatory response. J Clin Invest 1986; 77: 1014-1019.
59. Garlepp MJ, Leong CC. Biological and immunological aspects of malignant mesothelioma. Eur Respir J 1995; 8: 643-650.
60. Mossman BT, Bignon J, Corn M, Seaton A, Gee JBL. Asbestos: scientific developments and implications for public policy. Science 1990; 247: 294-301.
61. Artvinli M, Baris YI. Malignant mesothelioma in a small village in the Anatolien region in Turkey: an epidemiological study. J Natl Cancer Inst 1979; 63: 17-22.
62. Wagner JC. The discovery of the association between blue asbestos and mesotheliomas and the aftermath. J Ind Med 1991; 48: 399-403.
63. Tada T, Ohzeki S, Utsumi K, Takiiuchi H, Muramatsu M, Shimizu J. Transforming growth factor-beta induced inhibition of T-cell function. Susceptibility differences in T-cells of various phenotypes and functions and its relevance to immunosuppression in the tumour-bearing state. J Immunol 1991; 146: 1007-1082.
64. Bielefeld-Ohmann H, Fitzpatric DR, Marzo AL, Jarnicki AG, Musk AW, Robinson BWS. Potential for interferon-alpha-based therapy in mesothelioma: assessment in a murine model. J Interferon Cytokine Res 1995; 15: 213-223.
65. Bielefeld-Ohmann H, Fitzpatric DR, Marzo AL, et al. Patho- and immunobiology of malignant mesothelioma: characterisation of tumour infiltrating leukocytes and cytokine production in a murine model. Cancer Immunol Immunother 1994; 39: 347-359.
66. Jarnicki AG, Fitzpatric DR, Marzo AL, Robinson BWS, Bielefeld-Ohmann H. Surface antigen and cytokine profile of tumor infiltrating lymphocytes (TIL) in malignant mesothelioma. J Leuk Biol 1993; 54 (Suppl): 90-95.
67. Fitzpatrick DR, Bielefeld-Ohmann H, Himbeck RP, Jarnicki AG, Marzo AL, Robinson BWS. Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumour-infiltrating T-cells in malignant mesothelioma. Growth Factors 1994; 11: 29-44.
68. Guzman J, Bross KJ, Costabel U. Malignant pleural effusions due to small cell carcinoma of the lung. An immunohistochemical cell-surface analysis of lymphocytes and tumor cells. Acta Cytol 1990; 34; 497-501.
69. Gjomarkaj M, Pace E, Melis M, Spatafora M, D'Amico D, Toews GB. Dendritic cells with a potent accessory activity are present in human exudative malignant pleural effusions. Eur Respir J 1997; 10: 592-597.
70. Walker-Renard PB, Vaughan LM, Sahn SA. Chemical pleurodesis for malignant pleural effusions. Ann Intern Med 1994; 120: 56-64.
71. Rodriguez-Panadero F, Antony VB. Pleurodesis: state of the art. Eur Respir J 1997; 10: 1648-1654.
72. Strange C, Tomlinson JR, Wilson C, Harley R, Miller KS, Sahn SA. The history of experimental pleural injury with tetracycline, empyema, and carrageenan. Exp Mol Pathol 1989; 51: 205-219.
73. Rossi GA, Sacco O, Balzano E. Cell mediated immunity in malignant pleural effusions. Am Rev Respir Dis 1984; 129: 8A.
74. Kato H, Yamamura Y, Kin R, et al. Treatment of malignant ascitis and pleurisy by a streptococcal preparation OK-432 with fresh frozen plasma: a mechanism of polymorphonuclear leukocyte (PMN) accumulation. Intern J Immunopharmacol 1989; 11: 117-128.
75. Rodriquez-Panadero F, Segado A, Juan LM, Garcia IT, Castillo J. Failure of talc pleurodesis is associated with increased pleural fibrinolysis. Am J Respir Crit Care Med 1995; 151: 785-790.
76. Gray AJ, Bishop JE, Reeves JT, Mecham RP, Laurent GF. Partially degraded Fibrin(ogen) stimulates proliferation in vitro. Am J Respir Cell Mol Biol 1995; 12: 684-690.
77. Dang CV, Bell WR, Kaiser D, Wong A. Disorganization of cultured vascular endothelial cell monolayers by fibrinogen fragment D. Science 1985; 227: 1487-1490.
78. Sueshi KS, Nanno S, Tanaka K. Permeability enhancing and chemotactic activities of lower molecular weight degradation products of human fibrinogen. Thromb Haemost 1981; 45: 90-94.